Search research articles
Contact Us
Filters
Showing results (171-180 of 257) with videos related to
Page
of 26
Sort By:
Lancet (London, England)
|
February 7, 2021
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
Kristian Reich, Kim A Papp, Andrew Blauvelt, et al.
The Journal of Investigative Dermatology
|
November 17, 2015
Establishing an Academic-Industrial Stratified Medicine Consortium: Psoriasis Stratification to Optimize Relevant Therapy
Christopher E M Griffiths, Michael R Barnes, A David Burden, et al.
The British Journal of Dermatology
|
September 23, 2025
Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage)
Richard B Warren, Marjolein de Bruin-Weller, Athanasios Tsianakas, et al.
Dermatology and Therapy
|
January 17, 2025
Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study
Richard B Warren, Lev Pavlovsky, Antonio Costanzo, et al.
Dermatology and Therapy
|
November 8, 2024
Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study
Richard B Warren, Lev Pavlovsky, Antonio Costanzo, et al.
The Journal of Investigative Dermatology
|
February 22, 2023
Atopic Polygenic Risk Score Is Associated with Paradoxical Eczema Developing in Patients with Psoriasis Treated with Biologics
Ali Al-Janabi, Steve Eyre, Amy C Foulkes, et al.
The British Journal of Dermatology
|
November 20, 2024
Drug survival and safety of biosimilars for treating psoriasis compared with originator adalimumab: a multinational cohort study
Duc Binh Phan, Hugo Jourdain, Miguel Angel Descalzo-Gallego, et al.
The Journal of Investigative Dermatology
|
February 19, 2021
Chromatin Looping Links Target Genes with Genetic Risk Loci for Dermatological Traits
Chenfu Shi, Helen Ray-Jones, James Ding, et al.
The British Journal of Dermatology
|
September 9, 2022
Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials
Eric L Simpson, Joseph F Merola, Jonathan I Silverberg, et al.
Journal of the American Academy of Dermatology
|
July 12, 2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
April W Armstrong, Melinda Gooderham, Richard B Warren, et al.
Page
of 26
Search research articles
Search
Showing results (171-180 of 257) with videos related to
Sort By:
Page
of 26
Lancet (London, England)
|
February 7, 2021
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
Kristian Reich, Kim A Papp, Andrew Blauvelt, et al.
The Journal of Investigative Dermatology
|
November 17, 2015
Establishing an Academic-Industrial Stratified Medicine Consortium: Psoriasis Stratification to Optimize Relevant Therapy
Christopher E M Griffiths, Michael R Barnes, A David Burden, et al.
The British Journal of Dermatology
|
September 23, 2025
Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage)
Richard B Warren, Marjolein de Bruin-Weller, Athanasios Tsianakas, et al.
Dermatology and Therapy
|
January 17, 2025
Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study
Richard B Warren, Lev Pavlovsky, Antonio Costanzo, et al.
Dermatology and Therapy
|
November 8, 2024
Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study
Richard B Warren, Lev Pavlovsky, Antonio Costanzo, et al.
The Journal of Investigative Dermatology
|
February 22, 2023
Atopic Polygenic Risk Score Is Associated with Paradoxical Eczema Developing in Patients with Psoriasis Treated with Biologics
Ali Al-Janabi, Steve Eyre, Amy C Foulkes, et al.
The British Journal of Dermatology
|
November 20, 2024
Drug survival and safety of biosimilars for treating psoriasis compared with originator adalimumab: a multinational cohort study
Duc Binh Phan, Hugo Jourdain, Miguel Angel Descalzo-Gallego, et al.
The Journal of Investigative Dermatology
|
February 19, 2021
Chromatin Looping Links Target Genes with Genetic Risk Loci for Dermatological Traits
Chenfu Shi, Helen Ray-Jones, James Ding, et al.
The British Journal of Dermatology
|
September 9, 2022
Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials
Eric L Simpson, Joseph F Merola, Jonathan I Silverberg, et al.
Journal of the American Academy of Dermatology
|
July 12, 2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
April W Armstrong, Melinda Gooderham, Richard B Warren, et al.
Page
of 26